TRNR is expected to generate more than $50M in revenue in 2025 on a pro forma basis and achieve EBITDA profitability in H2 ‘25
Sportstech is founder-led, having achieved profitability and scale without raising capital and has successfully sold equipment to almost 3 million customers since 2012
TRNR Listing and global presence to help Sportstech accelerate growth beyond core markets, most notably the US; Sportstech's scaled, profitable business to drive step-change for TRNR top and bottom lines
Transaction delivers on previously-announced LOI, combines highly complementary businesses to create a scaled, international operation anchored in the US and Germany, the #1 and #2 fitness markets globally
Deal - TRNR's second within 12 months - advances its strategy for building shareholder value through accretive acquisitions of profitable, growth businesses in the fragmented global health & wellness market
TRNR CEO to discuss transaction at 2025 Connected: Health & Fitness Summit today in Los Angeles
Read MoreIntroduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall
Read More
MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has obstructed domestic cannabis research despite the Right To Try and the Medical Marijuana Research Expansion Act. MMJ accuses the DEA of bias in restricting MMJ to cultivate its proprietary marijuana cultivars necessary for research and pharmaceutical drug manufacturing. A pending federal court ruling in Rhode Island will set a significant precedent, challenging DEA authority and potentially easing regulatory barriers for MMJ's future cannabinoid drug development.
Read MoreA wholly owned subsidiary of Nitches Inc. (OTC:NICH), InTheZone Labs is at the forefront of a rising health movement as customers uncover powerful De-Aging effects from its premium nootropic formulations.
Read MoreMagdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026
Read MoreRevenues increased 14% for the quarter compared to prior year and 13% year-to-date
Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024
Year-to-date net loss decline of $1.1 million
GoCheck Kids, a leading provider of pediatric vision screening solutions, is proud to announce a major milestone: over 1 million vision screenings completed in 2024 and more than 6 million screenings performed since the company's inception.
Read More
Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.
Read More
This announcement underscores Dr. Shervin Naderi's dedication to delivering exceptional care and achieving outstanding results for his patients. As a 2025 Castle Connolly Top Doctor, Dr. Naderi continues to set the standard for excellence in facial plastic surgery, inspiring confidence and trust among patients nationwide.
Read More
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth.
Read More
EnvisionOne Vantage enables medical affairs professionals to benchmark their publication performance against other companies, providing crucial competitive intelligence and valuable insights for strategic adjustments to publication strategies.
Read MoreTrial taking place at Sheikh Khalifa Medical City, a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi
Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID
Proof-of-concept (POC) data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for these rare/orphan diseases
Read More
Ranked #1 in EHR & Digital Health Solutions by Black Book Research surveys of nearly 28,000 global EHR users-Leading Innovation Across All Spanish-Speaking Latin American Countries, Germany, Austria, Switzerland, Liechtenstein (DACHL), Portugal, the UK, and Italy with AI, Cloud, and Interoperability.
Read More